Long VITT

There is an increased rate of coagulation disorders following all COVID-19 vaccines. One example is Vaccine-induced immune thrombotic thrombocytopenia (VITT). It happens when the body's defense mechanisms incorrectly target and kill platelets, small cell fragments that aid in blood clotting. VITT can lead to significant morbidity and mortality due to the various thrombosis-related complications.


A 56-year-old man with a history of high blood pressure and high cholesterol developed left leg claudication and a persistent new right calf pain after receiving the first dose of the ChAdOx1 nCoV-19 vaccine, A right leg venous doppler ultrasound confirmed a great saphenous vein thrombosis with an extension to the femoral vein. CT angiogram showed an infrarenal aortic thrombus occluding 50% of the lumen and a left popliteal artery thrombosis without significant atherosclerosis. A CT pulmonary angiogram was done and revealed multiple segmental pulmonary embolisms. Brain imaging showed a cerebral vein thrombosis of the left sigmoid sinus with extension to the jugular vein without hemorrhage.

When the Polyspecific Anti-PF4 Immunoassay (Immucor) result was positive, VITT was quickly suspected. The PF4-SRA was also positive. Prednisone, intravenous immunoglobulin, argatroban, and rivaroxaban were used to treat the patient, who also underwent lower limb revascularization surgery. The clinical course was favorable despite PF4-SRA still being positive after successful surgical intervention. After receiving care, the patient was sent home.

After a 2-year follow-up, the patient developed thrombocytopenia and positive platelet-activation tests. He is not known for any relevant past medical history other than alcohol consumption and slight thrombocytopenia (130 × 109/L since 2015). It is unknown if the chronic platelet-activating anti-PF4 antibodies or the patient's habits are to blame for the continuous and progressively serious thrombocytopenia. Another case with recurrent episodes of thrombocytopenia and positive PF4-SRA over a 9-month follow-up period in a 69-year-old male was also reported. 

The authors suggested that long VITT diagnosis definition might include the persistence within patient serum/plasma of anti-PF4 platelet-activating antibodies with clinical manifestations (e.g., thrombocytopenia) for more than 3 months.


REFERENCES

Roberge G, Carrier M. Long VITT: A case report. Thromb Res. 2023 Jan 24;223:78-79. doi: 10.1016/j.thromres.2023.01.017. Epub ahead of print. PMID: 36709677; PMCID: PMC9870606.

Roberge G, Côté B, Calabrino A, Gilbert N, Gagnon N. Acute lower limb ischemia caused by vaccine-induced immune thrombotic thrombocytopenia: focus on perioperative considerations for 2 cases. Thrombosis Journal. 2022 Jul 4;20(1):38.

Gabarin N, Arnold DM, Nazy I, Warkentin TE. Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT). InSeminars in hematology 2022 Mar 7. WB Saunders.

Berild JD, Larsen VB, Thiesson EM, Lehtonen T, Grøsland M, Helgeland J, Wolhlfahrt J, Hansen JV, Palmu AA, Hviid A. Analysis of thromboembolic and thrombocytopenic events after the AZD1222, BNT162b2, and MRNA-1273 covid-19 vaccines in 3 Nordic countries. JAMA Network Open. 2022 Jun 1;5(6):e2217375-.

Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

Navigating the Tripledemic: JN.1, RSV, and Flu Update

Image
The respiratory viruses are out there.  Wastewater viral activity levels for COVID-19 , as reported by the Centers for Disease Control and Prevention, have reached the highest point since the Omicron surge in 2022. The levels are also high in Canada . The three primary respiratory illnesses continue to circulate at very high levels. But despite the triple threat of  SARS-Cov-2, respiratory syncytial virus ( RSV ) and the flu , there is a notable lack of community attention.   JN.1 (Pirola,  BA.2.86 ,  with additional L455S mutation, descending from a  de-escalated  variant of concern BA.2), initially detected on August 25 2023, has evolved from a variant under monitoring to a  variant of interest. Variants like Acrux (XBB.2.3, that began to spread worldwide soon after WHO declared the end of the pandemic) are  no longer relevant , but a few now less prevalent variants such as  Centaurus  (BA.2.75) and XBB, a hybrid of Centaurus with BA.2 lineage, that  gave rise to  Eris , its descend
Read more

The offshoots of JN.1 in the Evolutionary Trajectory of COVID-19

Image
While the current SARS-COV-2 viral activity levels may seem reassuring ( back to the levels seen in October-November 2023 ), the evolving world of JN.1 offshoots, where the next generation of variants is taking shape, presents a compelling case for anticipating the potential challenges that lie ahead.  From the widespread presence of JN.1.16 across continents to the emerging dominance of JN.1.13 in the U.S., the current variant landscape is rapidly shifting, although the potential implications for the future are not quite clear.  The roots of the pandemic can be traced back to lineage A, with many initial sequences originating from China and subsequently spreading globally, including to regions such as South East Asia, Japan, South Korea, Australia, the USA, and Europe. Lineage B followed as the second major haplotype, with subsequent evolutions leading to the emergence of various sublineages. In 2020, we witnessed the emergence of variants such as Alpha (B.1.1.7) and Delta (B.1.617.2
Read more